Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer.

Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI:10.1080/17435889.2024.2370225

Druva Sarika Rongala, Suyash M Patil, Nitesh K Kunda

{"title":"Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer.","authors":"Druva Sarika Rongala, Suyash M Patil, Nitesh K Kunda","doi":"10.1080/17435889.2024.2370225","DOIUrl":null,"url":null,"abstract":"Background: Development of an inhalable nanoformulation of dacomitinib (DMB) encapsulated in poly-(lactic-co-glycolic acid) nanoparticles (NPs) to improve solubility, facilitate direct lung delivery and overcome the systemic adverse effects.Methods: DMB-loaded poly-(lactic-co-glycolic acid) NPs were prepared using solvent evaporation and characterized for particle size, polydispersity index and zeta-potential. The NPs were evaluated for in vitro drug release, aerosolization performance and in vitro efficacy studies.Results: The NPs showed excellent particle characteristics and displayed a cumulative release of ∼40% in 5 days. The NPs demonstrated a mass median aerodynamic diameter of ∼3 μm and fine particle fraction of ∼80%. Further, in vitro cell culture studies showed improved cytotoxic potential of DMB-loaded NPs compared with free drug.Conclusion: The study underscores the potential of DMB-loaded NPs as a viable approach for non-small cell lung cancer treatment.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11389738/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2370225","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Development of an inhalable nanoformulation of dacomitinib (DMB) encapsulated in poly-(lactic-co-glycolic acid) nanoparticles (NPs) to improve solubility, facilitate direct lung delivery and overcome the systemic adverse effects.Methods: DMB-loaded poly-(lactic-co-glycolic acid) NPs were prepared using solvent evaporation and characterized for particle size, polydispersity index and zeta-potential. The NPs were evaluated for in vitro drug release, aerosolization performance and in vitro efficacy studies.Results: The NPs showed excellent particle characteristics and displayed a cumulative release of ∼40% in 5 days. The NPs demonstrated a mass median aerodynamic diameter of ∼3 μm and fine particle fraction of ∼80%. Further, in vitro cell culture studies showed improved cytotoxic potential of DMB-loaded NPs compared with free drug.Conclusion: The study underscores the potential of DMB-loaded NPs as a viable approach for non-small cell lung cancer treatment.

查看原文本刊更多论文

口服吸入达科米替尼纳米载体作为非小细胞肺癌的治疗策略。

背景：开发一种可吸入的纳米制剂，将达科替尼（DMB）封装在聚（乳酸-共-乙醇酸）纳米颗粒（NPs）中，以提高溶解度、促进直接肺部给药并克服全身不良反应。研究方法采用溶剂蒸发法制备了负载 DMB 的聚（乳酸-共聚-乙醇酸）NPs，并对其粒度、多分散指数和 zeta 电位进行了表征。对 NPs 的体外药物释放、气溶胶性能和体外药效研究进行了评估。结果显示NPs 表现出优异的颗粒特性，5 天内的累积释放量达到 40%。NPs 的质量中值气动直径为 ∼3 μm，细颗粒比例为 ∼80%。此外，体外细胞培养研究表明，与游离药物相比，负载 DMB 的 NPs 具有更好的细胞毒性潜力。结论该研究强调了 DMB 负载 NPs 作为治疗非小细胞肺癌的一种可行方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量